When tested in a mouse model of breast cancer, the doxorubicin-loaded nanoparticles caused fewer side effects than free ...

Scientists at Xi'an Jiaotong-Liverpool University (XJTLU) and Nanjing University in China have developed a new drug delivery ...

Oncologists vary widely in treating DLBCL with cardiomyopathy, often diverging from guidelines due to limited evidence on ...

Medicus Pharma submitted a product development plan to the FDA for an investigational new animal drug designation.

Doxorubucin is an effective therapeutic in cancer treatment, but it can cause cardiotoxicity and damage the mitochondrial machinery. A new patient-derived and mitochondria-rich human induced ...

Medicus Pharma (NASDAQ: MDCX) paints the picture of a small-cap biotech transitioning from concept to execution. The recent capital raise was non-dilutive and immediately followed by a key regulatory ...

Osaka: Takeda has received approval from the European Commission (EC) for ADCETRIS (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and ...

The European Commission (EC) has approved Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) plus the chemotherapy regimen for adults with newly diagnosed Stage IIb Hodgkin's ...

MATHEMATICAL MODEL Biologist Regina Joyce Ferrer from the University of the Philippines analyzes breast cancer organoids. —MICHAEL VELARDE MANILA, Philippines — Biologists from the University ...

Doxorubicin is a type of anthracycline chemotherapy drug used to treat certain types of solid tumors and blood cancers. It has a number of side effects, some more serious than others. Experts ...

Progression-free survival was longer in the doxorubicin-trabectedin group versus the doxorubicin group, in a finding consistent with earlier reports (12 versus six months; adjusted hazard ratio ...